Bisphosphonates Use After Total Joint Arthroplasty
Postoperative Use of Bisphosphonates Reduces Adverse Outcome After Primary Total Joint Arthroplasty: A Nationwide Population-based Cohort Study
Background Bisphosphonates has been associated with a decreased risk of revision total joint replacements because of its effects on decreased periprosthetic bone loss and prosthetic migration. However, the results in the early literature are inconsistent and the influence of bisphosphonates on associated complications and subsequent total joint arthroplasty (TJA) remains unknown. This study is to investigate the association between the use of bisphosphonates and risk of adverse outcomes after primary TJA.
Materials and Methods This matched cohort study utilized National Health Insurance Research Database in Taiwan to identify patients who underwent primary TJA over a 15-year period (January 2000- December 2015 inclusive). Study participants were further categorized into two groups: bisphosphonates users and nonusers, using propensity score matching. The Kaplan-Meier curve analysis and adjusted hazard ratios (aHR) of revision surgery, adverse outcomes of primary surgery and undergoing subsequent TJA were calculated using Cox regression analysis.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 11472
- Tri-Service General Hospital, National Defense Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients who underwent primary total joint arthroplasty during the study period (January 1, 2000 to December 31, 2015).
Exclusion Criteria:
- Patients with total joint arthroplasty before the index date,
- Patients with existing pathologic fracture, nonunion of fracture and partial joint replacement,
- Patients who were lost to follow-up
- Patients < 40 years old
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
bisphosphonates users
Patients who underwent primary total joint arthroplasty with bisphosphonates use
|
|
|
bisphosphonates nonusers
Patients who underwent primary total joint arthroplasty without bisphosphonates use
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
revision rate of joint arthroplasty
Time Frame: a 15-year period (January 2000- December 2015 inclusive)
|
revision rate of joint arthroplasty after primary surgery
|
a 15-year period (January 2000- December 2015 inclusive)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The rate of secondary total joint arthroplasty
Time Frame: a 15-year period (January 2000- December 2015 inclusive)
|
The rate of secondary total joint arthroplasty
|
a 15-year period (January 2000- December 2015 inclusive)
|
|
The rate of periprosthetic joint infection
Time Frame: a 15-year period (January 2000- December 2015 inclusive)
|
The rate of periprosthetic joint infection
|
a 15-year period (January 2000- December 2015 inclusive)
|
|
The rate of periprosthetic fracture
Time Frame: a 15-year period (January 2000- December 2015 inclusive)
|
The rate of periprosthetic fracture
|
a 15-year period (January 2000- December 2015 inclusive)
|
|
Mortality rate
Time Frame: a 15-year period (January 2000- December 2015 inclusive)
|
Mortality rate
|
a 15-year period (January 2000- December 2015 inclusive)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TSGH-D-110103
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.